Significance of postoperative adjuvant chemotherapy with an oxaliplatin-based regimen after simultaneous curative resection for colorectal cancer and synchronous colorectal liver metastasis: a propensity score matching analysis

Table 1 Details of the regimens of postoperative adjuvant chemotherapy (POAC)

Group	Regimen	No. of patients (%)		No. of cycles/months ^{a) b)}
L-OHP (+)	CapeOX	25	− 26.60%	8 cycles	(2–25)
	FOLFOX	22	− 23.40%	12 cycles	(1–14)
	Subtotal	47	− 50.00%
L-OHP (−)	UFT/LV	38	− 40.40%	6 months	(1–24)
	S-1	7	− 7.40%	12 months	(2–24)
	Capecitabine	2	− 2.10%	11 months	(10, 12)
	Subtotal	47	− 50.00%
	Total	94	− 100%

^aMedian (minimum–maximum)
^bDiscontinuation was included due to recurrence or adverse events
The common regimens in the L-OHP (+) group were CapeOX (n = 25 patients, 26.6%) and FOLFOX (n = 22, 23.4%), and those in the L-OHP (−) group were UFT/LV (n = 38, 40.4%), S-1 (n = 7, 7.4%) and capecitabine (n = 2, 2.1%). The median numbers of cycles in each regimen in the L-OHP (+) group were 8 for CapeOX and 12 for FOLFOX. The median periods for each regimen in the L-OHP (−) group were 6 months for UFT/LV, 12 months for S-1 and 11 months for capecitabine (including discontinuation due to recurrence or adverse events)

ISSN: 1471-2482